Brief: Mesoblast Seeks Trading Halt
01/08/2023 23:43
Aug 2 (Reuters) - Mesoblast Ltd MSB.AX :
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON U.S. FDA'S
REVIEW OF
BIOLOGICS LICENSE APPLICATION RESUBMISSION FOR REMESTEMCEL-L
Source text for Eikon: ID:nASX6xByKR
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M